Walleye Capital’s LumiraDx Limited Warrant LMDXW Stock Holding History

Walleye Capital’s Portfolio LMDXW Stock Details LMDXW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-30,000	Closed	-$258	–	6153
2023 Q4	$258	Hold	30,000	–	–	﹤0.01%	4859
2023 Q3	$870	Hold	30,000	–	–	﹤0.01%	4767
2023 Q2	$897	Hold	30,000	–	–	﹤0.01%	4201
2023 Q1	$3.52K	Hold	30,000	–	–	﹤0.01%	3706
2022 Q4	$1.77K	Hold	30,000	–	–	﹤0.01%	3004
2022 Q3	$3K	Hold	30,000	–	–	﹤0.01%	3023
2022 Q2	$27K	Sell	30,000 -52,840	-64%	-$45.7K	﹤0.01%	1876
2022 Q1	$72K	Hold	82,840	–	–	﹤0.01%	1803
2021 Q4	$150K	Buy	82,840 +46,990	+131%	+$75.8K	﹤0.01%	1565
2021 Q3	$42	Buy	+35,850	New	+$41.6K	﹤0.01%	1408

Other funds holding LMDXW

CVS Health Woonsocket, Rhode Island $212M AUM 19.39% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

Walleye Capital's LMDXW Position: Q1 2024 in Review

Walleye Capital sold out of LumiraDx Limited Warrant (LMDXW) in Q1 2024, closing a stake of 30,000 shares — an estimated $258 sold.

Walleye Capital first reported a position in LMDXW in Q3 2021 and held it in 10 quarters. The position peaked at $150K in Q4 2021. 4 funds tracked by Wall St. Rank hold LMDXW as of Q1 2024.

Walleye Capital reported no remaining LumiraDx Limited Warrant position as of Q1 2024 after selling out during the quarter.
Walleye Capital sold 30,000 LumiraDx Limited Warrant shares in Q1 2024, an estimated $258.
Walleye Capital first reported a position in LumiraDx Limited Warrant in Q3 2021 and held it in 10 quarters.
Walleye Capital's LumiraDx Limited Warrant position peaked at $150K in Q4 2021.
4 funds tracked by Wall St. Rank held LumiraDx Limited Warrant as of Q1 2024.

Based on Walleye Capital's 13F filing for Q1 2024, filed 15 May 2024.